Summary

Smart Inhalers Market Summary

The global smart inhalers market size was estimated at USD 18.4 billion in 2024 and is projected to reach USD 91.9 billion by 2033, growing at a CAGR of 19.6% from 2025 to 2033. The rising prevalence of chronic respiratory diseases (CRDs) globally, the development of technologically advanced products, and the growing adoption of digital solutions in the healthcare sector are expected to contribute to the market's growth.

According to estimates from the American Lung Association, in 2022, 11.7 million people, or 4.6% of adults, reported a diagnosis of COPD, including chronic bronchitis and emphysema. In addition, the WHO estimates that potentially fatal respiratory diseases, including COPD, lung cancer, and tuberculosis, will account for about one in five deaths worldwide by 2030.

The increasing focus on developing smart inhalers and a rise in initiatives by key market players for R&D efforts drive the demand for smart inhalers. In addition, more companies are integrating digital technologies into their product offerings to enhance medication effectiveness and the management of asthma and COPD. For instance, in April 2022, Aptar Pharma, a market player, introduced HeroTracker Sense, a chronic respiratory digital e-health solution that converts a conventional metered dose inhaler into a smart inhaler.

Moreover, various research studies highlighting the benefits of adopting smart inhalers, such as assisting patients in treatment adherence and controlling symptoms, also contribute to the market growth. For instance, a 2020 Cleveland Clinic study discovered that patients with COPD using the Propeller company’s smart inhalers had a noticeably lower risk of being admitted to the hospital, with a nearly 35% drop in visits compared to the prior year.

Furthermore, increasing adoption of digital health technologies and connected devices is enabling better patient adherence, remote monitoring, and personalized treatment plans. Integration of Bluetooth and sensor-based technologies allows healthcare providers to track inhaler usage and optimize therapy outcomes. Supportive government initiatives, growing awareness about disease management, and collaborations between pharmaceutical companies and tech firms are further accelerating market expansion. In addition, the shift toward value-based care is encouraging the adoption of smart inhalers.

Global Smart Inhalers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global smart inhalers market report based on type, indication, distribution channel, end use, and region.

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Dry Powdered Inhalers (DPIs)
• Metered Dose Inhalers (MDIs)
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Asthma
• COPD
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Homecare Settings
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Sweden
o Denmark
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East and Africa
o Saudi Arabia
o South Africa
o UAE
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.5. Details of primary research
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.1.1. Approach 1: Commodity flow approach
1.7.2. Volume price analysis (Model 2)
1.7.2.1. Approach 2: Volume price analysis
1.8. Research Scope and Assumptions
1.8.1. List of Secondary Sources
1.8.2. List of Primary Sources
1.8.3. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type Outlook
2.2.2. Indication Outlook
2.2.3. Distribution Channel Outlook
2.2.4. End Use Outlook
2.2.5. Regional Outlook
2.3. Competitive Insights
Chapter 3. Smart Inhalers Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Industry Analysis
3.2.1. User Perspective Analysis
3.2.2. Key End Users
3.3. Technology Outlook
3.4. Regulatory Framework
3.5. Market Dynamics
3.5.1. Market Drivers Analysis
3.5.1.1. Rising prevalence of respiratory diseases
3.5.1.2. Development of technologically advanced solutions
3.5.1.3. Growing adoption of digital health technologies
3.5.2. Market Restraints Analysis
3.5.2.1. Higher cost than traditional inhalers
3.5.3. Industry Challenges and Opportunity Analysis
3.6. Smart Inhalers Market Analysis Tools
3.6.1. Porter’s Analysis
3.6.1.1. Bargaining power of the suppliers
3.6.1.2. Bargaining power of the buyers
3.6.1.3. Threats of substitution
3.6.1.4. Threats from new entrants
3.6.1.5. Competitive rivalry
3.6.2. PESTEL Analysis
3.6.2.1. Political landscape
3.6.2.2. Economic and Social landscape
3.6.2.3. Technological landscape
3.6.2.4. Environmental landscape
3.6.2.5. Legal landscape
Chapter 4. Smart Inhalers Market: Type Estimates & Trend Analysis
4.1. Definition and Scope
4.2. Type Market Share Analysis, 2024 & 2033
4.3. Segment Dashboard
4.4. Smart Inhalers Market: By Type, 2021 to 2033
4.4.1. Dry Powdered Inhalers (DPIs)
4.4.1.1. Dry Powdered Inhalers (DPIs) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
4.4.2. Metered Dose Inhalers (MDIs)
4.4.2.1. Metered Dose Inhalers (MDIs) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 5. Smart Inhalers Market: Indication Estimates & Trend Analysis
5.1. Definition and Scope
5.2. Indication Market Share Analysis, 2024 & 2033
5.3. Segment Dashboard
5.4. Smart Inhalers Market: By Indication, 2021 to 2033
5.4.1. Asthma
5.4.1.1. Asthma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.4.2. COPD
5.4.2.1. COPD Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.4.3. Others
5.4.3.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 6. Smart Inhalers Market: Distribution Channel Estimates& Trend Analysis
6.1. Definition and Scope
6.2. Distribution Channel Market Share Analysis, 2024 & 2033
6.3. Segment Dashboard
6.4. Smart Inhalers Market: By Distribution Channel, 2021 to 2033
6.4.1. Hospital Pharmacies
6.4.1.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.4.2. Retail Pharmacies
6.4.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.4.3. Online Pharmacies
6.4.3.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 7. Smart Inhalers Market: End Use Estimates& Trend Analysis
7.1. Definition and Scope
7.2. End Use Market Share Analysis, 2024 & 2033
7.3. Segment Dashboard
7.4. Smart Inhalers Market: By End Use, 2021 to 2033
7.4.1. Hospital
7.4.1.1. Hospital Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.2. Homecare Settings
7.4.2.1. Homecare Settings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.4.3. Others
7.4.3.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 8. Smart Inhalers Market: Regional Estimates & Trend Analysis by Country, Type, Indication, Distribution Channel, End Use
8.1. Definition and Scope
8.2. Regional Market Share Analysis, 2024 & 2033
8.3. Regional Market Dashboard
8.4. Regional Market Snapshot
8.5. SWOT Analysis
8.5.1. North America
8.5.2. Europe
8.5.3. Asia Pacific
8.5.4. Latin America
8.5.5. Middle East & Africa
8.6. Smart Inhalers Market Share, By Region, 2024 & 2033 (USD Billion)
8.7. North America
8.7.1. North America Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.7.2. U.S.
8.7.2.1. Key Country Dynamics
8.7.2.2. Regulatory Landscape/Reimbursement Scenario
8.7.2.3. Competitive Insights
8.7.2.4. U.S. Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.7.3. Canada
8.7.3.1. Key Country Dynamics
8.7.3.2. Regulatory Landscape/Reimbursement Scenario
8.7.3.3. Competitive Insights
8.7.3.4. Canada Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.7.4. Mexico
8.7.4.1. Key Country Dynamics
8.7.4.2. Regulatory Landscape/Reimbursement Scenario
8.7.4.3. Competitive Insights
8.7.4.4. Mexico Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8. Europe
8.8.1. Europe Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8.2. UK
8.8.2.1. Key Country Dynamics
8.8.2.2. Regulatory Landscape/Reimbursement Scenario
8.8.2.3. Competitive Insights
8.8.2.4. UK Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8.3. Germany
8.8.3.1. Key Country Dynamics
8.8.3.2. Regulatory Landscape/Reimbursement Scenario
8.8.3.3. Competitive Insights
8.8.3.4. Germany Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8.4. France
8.8.4.1. Key Country Dynamics
8.8.4.2. Regulatory Landscape/Reimbursement Scenario
8.8.4.3. Competitive Insights
8.8.4.4. France Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8.5. Italy
8.8.5.1. Key Country Dynamics
8.8.5.2. Regulatory Landscape/Reimbursement Scenario
8.8.5.3. Competitive Insights
8.8.5.4. Italy Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8.6. Spain
8.8.6.1. Key Country Dynamics
8.8.6.2. Regulatory Landscape/Reimbursement Scenario
8.8.6.3. Competitive Insights
8.8.6.4. Spain Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8.7. Sweden
8.8.7.1. Key Country Dynamics
8.8.7.2. Regulatory Landscape/Reimbursement Scenario
8.8.7.3. Competitive Insights
8.8.7.4. Sweden Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8.8. Denmark
8.8.8.1. Key Country Dynamics
8.8.8.2. Regulatory Landscape/Reimbursement Scenario
8.8.8.3. Competitive Insights
8.8.8.4. Denmark Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.8.9. Norway
8.8.9.1. Key Country Dynamics
8.8.9.2. Regulatory Landscape/Reimbursement Scenario
8.8.9.3. Competitive Insights
8.8.9.4. Norway Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.9. Asia Pacific
8.9.1. Asia Pacific Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.9.2. China
8.9.2.1. Key Country Dynamics
8.9.2.2. Regulatory Landscape/Reimbursement Scenario
8.9.2.3. Competitive Insights
8.9.2.4. China Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.9.3. Japan
8.9.3.1. Key Country Dynamics
8.9.3.2. Regulatory Landscape/Reimbursement Scenario
8.9.3.3. Competitive Insights
8.9.3.4. Japan Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.9.4. India
8.9.4.1. Key Country Dynamics
8.9.4.2. Regulatory Landscape/Reimbursement Scenario
8.9.4.3. Competitive Insights
8.9.4.4. India Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.9.5. South Korea
8.9.5.1. Key Country Dynamics
8.9.5.2. Regulatory Landscape/Reimbursement Scenario
8.9.5.3. Competitive Insights
8.9.5.4. South Korea Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.9.6. Australia
8.9.6.1. Key Country Dynamics
8.9.6.2. Regulatory Landscape/Reimbursement Scenario
8.9.6.3. Competitive Insights
8.9.6.4. Australia Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.9.7. Thailand
8.9.7.1. Key Country Dynamics
8.9.7.2. Regulatory Landscape/Reimbursement Scenario
8.9.7.3. Competitive Insights
8.9.7.4. Thailand Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.10. Latin America
8.10.1. Latin America Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.10.2. Brazil
8.10.2.1. Key Country Dynamics
8.10.2.2. Regulatory Landscape/Reimbursement Scenario
8.10.2.3. Competitive Insights
8.10.2.4. Brazil Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.10.3. Argentina
8.10.3.1. Key Country Dynamics
8.10.3.2. Regulatory Landscape/Reimbursement Scenario
8.10.3.3. Competitive Insights
8.10.3.4. Argentina Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.11. Middle East and Africa
8.11.1. Middle East and Africa Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.11.2. South Africa
8.11.2.1. Key Country Dynamics
8.11.2.2. Regulatory Landscape/Reimbursement Scenario
8.11.2.3. Competitive Insights
8.11.2.4. South Africa Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.11.3. Saudi Arabia
8.11.3.1. Key Country Dynamics
8.11.3.2. Regulatory Landscape/Reimbursement Scenario
8.11.3.3. Competitive Insights
8.11.3.4. Saudi Arabia Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.11.4. UAE
8.11.4.1. Key Country Dynamics
8.11.4.2. Regulatory Landscape/Reimbursement Scenario
8.11.4.3. Competitive Insights
8.11.4.4. UAE Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.11.5. Kuwait
8.11.5.1. Key Country Dynamics
8.11.5.2. Regulatory Landscape/Reimbursement Scenario
8.11.5.3. Competitive Insights
8.11.5.4. UAE Smart Inhalers Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Market Share Analysis, 2024 (%)
9.4. Company Heat Map Analysis
9.5. Strategy Mapping
9.5.1. Expansion
9.5.2. Mergers & Acquisition
9.5.3. Partnerships & Collaborations
9.5.4. New Product Launches
9.5.5. Research And Development
9.6. Company Profiles
9.6.1. Presspart Verwaltungs GmbH.
9.6.1.1. Participant’s Overview
9.6.1.2. Financial Performance
9.6.1.3. Product Benchmarking
9.6.1.4. Recent Developments
9.6.2. Personal Air Quality Systems Pvt Ltd
9.6.2.1. Participant’s Overview
9.6.2.2. Financial Performance
9.6.2.3. Product Benchmarking
9.6.2.4. Recent Developments
9.6.3. COHERO Health Inc. (AptarGroup, Inc.)
9.6.3.1. Participant’s Overview
9.6.3.2. Financial Performance
9.6.3.3. Product Benchmarking
9.6.3.4. Recent Developments
9.6.4. Cognita Labs
9.6.4.1. Participant’s Overview
9.6.4.2. Financial Performance
9.6.4.3. Product Benchmarking
9.6.4.4. Recent Developments
9.6.5. Adherium
9.6.5.1. Participant’s Overview
9.6.5.2. Financial Performance
9.6.5.3. Product Benchmarking
9.6.5.4. Recent Developments
9.6.6. Amiko Digital Health Limited.
9.6.6.1. Participant’s Overview
9.6.6.2. Financial Performance
9.6.6.3. Product Benchmarking
9.6.6.4. Recent Developments
9.6.7. Teva Pharmaceuticals Industries Ltd.
9.6.7.1. Participant’s Overview
9.6.7.2. Financial Performance
9.6.7.3. Product Benchmarking
9.6.7.4. Recent Developments
9.6.8. Propeller Health (ResMed)
9.6.8.1. Participant’s Overview
9.6.8.2. Financial Performance
9.6.8.3. Product Benchmarking
9.6.8.4. Recent Developments
9.6.9. Novartis AG
9.6.9.1. Participant’s Overview
9.6.9.2. Financial Performance
9.6.9.3. Product Benchmarking
9.6.9.4. Recent Developments
9.6.10. Pneuma Respiratory Inc.
9.6.10.1. Participant’s Overview
9.6.10.2. Financial Performance
9.6.10.3. Product Benchmarking
9.6.10.4. Recent Developments
9.6.11. 3M
9.6.11.1. Participant’s Overview
9.6.11.2. Financial Performance
9.6.11.3. Product Benchmarking
9.6.11.4. Recent Developments
9.6.12. AireHealth, Inc.
9.6.12.1. Participant’s Overview
9.6.12.2. Financial Performance
9.6.12.3. Product Benchmarking
9.6.12.4. Recent Developments
9.6.13. FindAir Sp. z o.o
9.6.13.1. Participant’s Overview
9.6.13.2. Financial Performance
9.6.13.3. Product Benchmarking
9.6.13.4. Recent Developments